Articles and application notes
6 Misconceptions about automating cell therapy manufacturing
By using automation to minimize human interaction and time and resource requirements, you can increase your product’s speed to market and mitigate many of the risks and costs associated with commercialization.
AAV production using microcarriers
Large-scale AAV production processes are needed to industrialize gene therapies. This customer case study describes microcarrier culture in a 1 L bioreactor.
Apheresis variability control
Reduce variability in cell therapy manufacturing with standardized, automated management of apheresis product and process control strategies for MNC enrichment.
CAR T cells: closed and semi-automated processing
A robust workflow that can be adapted for cGMP compliance in commercial production. Achieves 1 × 1010 expanded T cells in 8 days.
CAR T cell process development study
Manual, open processing is not ideal for commercial production of chimeric antigen receptor (CAR T) cells. This study describes development of a closed and semi-automated process that can be adapted for GMP compliance and CAR T developers’ needs.
CBMG and Cytiva collaboration
CBMG accelerates cell therapy manufacturing with Cytiva’s start-to-finish FlexFactory for cellular therapies.
Consistent cord blood cryopreservation
Customer study shows reproducible cord blood freezing without liquid nitrogen.
Going liquid nitrogen-free for low-impact cryopreservation
Switching to a liquid nitrogen-free controlled-rate freezer can reduce carbon emissions by 87% over 10 yr and decrease operating costs by up to 97%. Read our study to see how you could minimize the environmental impact of your cryopreservation.
Cryopreservation techniques to maximize T-cell viability
T-cell cryopreservation is a critical step in cell therapy storage and transport. We share tested cooling techniques and tips to maximize cell viability, including how quickly to freeze cells and when to stop.
Developments in cell expansion for cell processing
Expand your knowledge on perfusion, our rocking technology and more by reading through our latest papers and posters.
Enabling LN2-free large-volume cryopreservation in vials
Cooling protocol and proof-of-concept study for the cryopreservation of large-volume biological samples in cryovials. Achieve high and consistent post-thaw recovery of up to 50 mL in this liquid nitrogen-free cell freezing method.
How and when to get started with GMP
Two cell therapy experts provide practical advice on when and how to start thinking about compliance with good manufacturing practices (GMP).
How to optimize and scale up AAV production: panel discussion
Leaders from academia and industry engage on topics from technology to ways of working
Interrupted cooling in cryopreservation
How does a power interruption during cooling affect post-thaw cell viability? This study demonstrates minimal effect of power outages and interrupted cooling during cryopreservation when using a VIA Freeze controlled-rate freezer.
Is a rapid cooling step needed?
This study shows comparable results when freezing cells with or without a rapid-cooling nucleation step.
Lentiviral vector upstream process
Upstream lentiviral vector process with stable producer cell line that can be adapted for commercial manufacturing. Scales linearly from 5 to 28 L in Xcellerex bioreactors yielding ≥ 1010 TU/L of LV-GFP.
Liquid nitrogen-free cryogenic shipping of cell products
We share results from evaluation trials conducted by CSL Behring using the VIA Capsule™ system for liquid-nitrogen free cryogenic shipping and temporary storage of cellular products.
Natural killer cells manufacturing
Workflow for NK cell production from apheresis units. Isolation, xeno-free expansion, harvest, and cryopreservation amenable to GMP manufacturing.
Oncolytic adenovirus production
Customer case study describes a robust upstream process and downstream process for oncolytic adenovirus production. Purity of final samples meets regulatory requirements.
Optimizing recovery on the Sepax™ cell processing system
Review our recent study highlighting a closed and automated process for cell therapy dilution, concentration, and washing steps using the CultureWash C-Pro application on the Sepax C-Pro cell processing system.
Producing consistent and compliant cell therapies
A new software platform is designed to simplify cell therapy processes. It offers many features and a single digital space to support both consistent production and compliance with regulations such as cGMP.
Scalable AAV production process for gene therapy
See how we developed an AAV cell culture process that successfully scaled to 20 L for several serotypes
Security of supply in cell and gene therapy manufacturing
Building an adequate supply chain with the necessary equipment and protocols is critical for companies pursuing cell and gene therapies. Cytiva realized the importance of this need and implemented a Security of supply program.
The Supply Chain Challenge
Overcoming the challenges of manufacturing and administering a complex product to any patient is critical for delivering cell therapies. Here two industry experts provide practical advice on strategies to meet supply chain challenges.
TIL sample collection and processing
There is an opportunity to automate and standardize workflow steps to improve outcomes of tumor-infiltrating lymphocyte (TIL) therapies.
Tumor-infiltrating lymphocytes as cell therapies
TILs are showing promise as cancer treatments for solid tumors. Learn what they are and how they differ from CAR T cells.
Unifying cell therapy logistics and manufacturing
For cell and gene therapies, the supply chain and logistics are critical. Collaboration is the key to solving data management and process variability challenges.